Advertisement

Electroporation-Based CRISPR/Cas9 Gene Editing Using Cas9 Protein and Chemically Modified sgRNAs

  • Anders Laustsen
  • Rasmus O. BakEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1961)

Abstract

CRISPR/Cas9 is an effective and easy-to-use tool for editing the genome of many human cancer cell lines. However, in some hard-to-transfect cell lines and primary cells, gene editing is more challenging. This protocol details an electroporation-based protocol for the delivery of Cas9 protein from Streptococcus pyogenes complexed with chemically modified sgRNAs. We have found this protocol to work very efficiently in numerous cell lines and primary cells that are difficult to transfect by conventional chemical-based transfection methods.

Key words

CRISPR/Cas9 Gene editing Chemically modified sgRNAs Electroporation Nucleoporation Gene knockout 

Notes

Acknowledgments

R.O.B. gratefully acknowledges the support from a Lundbeck Foundation Fellowship (R238-2016-3349), an AIAS-COFUND (Marie Curie) fellowship from Aarhus Institute of Advanced Studies (AIAS) co-funded by Aarhus University’s Research Foundation and the European Union’s seventh Framework Program under grant agreement no 609033, the Novo Nordisk Foundation (NNF17OC0028894), Innovation Fund Denmark (8056-00010B), the Carlsberg Foundation (CF17-0129), Slagtermester Max Wørzner og Hustru Inger Wørzners Mindelegat, The AP Møller Foundation, and the Riisfort Foundation.

References

  1. 1.
    Barrangou R, May AP (2015) Unraveling the potential of CRISPR-Cas9 for gene therapy. Expert Opin Biol Ther 15(3):311–314. https://doi.org/10.1517/14712598.2015.994501CrossRefPubMedGoogle Scholar
  2. 2.
    Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, Vrbanac V, Garrison BS, Stortchevoi A, Bryder D, Musunuru K, Brand H, Tager AM, Allen TM, Talkowski ME, Rossi DJ, Cowan CA (2014) Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15(5):643–652. https://doi.org/10.1016/j.stem.2014.10.004CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478(7370):515–518. https://doi.org/10.1038/nature10429CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168(9):4531–4537CrossRefGoogle Scholar
  5. 5.
    Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33(9):985–989. https://doi.org/10.1038/nbt.3290CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kim S, Kim D, Cho SW, Kim J, Kim JS (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24(6):1012–1019. https://doi.org/10.1101/gr.171322.113CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG (2017) Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol 35(12):1179–1187. https://doi.org/10.1038/nbt.4005CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lee K, Mackley VA, Rao A, Chong AT, Dewitt MA, Corn JE, Murthy N (2017) Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. elife 6:e25312. https://doi.org/10.7554/eLife.25312CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wong TK, Neumann E (1982) Electric field mediated gene transfer. Biochem Biophys Res Commun 107(2):584–587CrossRefGoogle Scholar
  10. 10.
    Chicaybam L, Sodre AL, Curzio BA, Bonamino MH (2013) An efficient low cost method for gene transfer to T lymphocytes. PLoS One 8(3):e60298. https://doi.org/10.1371/journal.pone.0060298CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bak RO, Porteus MH (2017) CRISPR-mediated integration of large gene cassettes using AAV donor vectors. Cell Rep 20(3):750–756. https://doi.org/10.1016/j.celrep.2017.06.064CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281–2308. https://doi.org/10.1038/nprot.2013.143CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Brinkman EK, Chen T, Amendola M, van Steensel B (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 42(22):e168. https://doi.org/10.1093/nar/gku936CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bak RO, Dever DP, Porteus MH (2018) CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc 13(2):358–376. https://doi.org/10.1038/nprot.2017.143CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of BiomedicineAarhus UniversityAarhusDenmark
  2. 2.Aarhus Institute of Advanced Studies (AIAS)Aarhus UniversityAarhusDenmark

Personalised recommendations